BioMarin Pharma (BMRN) Tops Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.31 -1.95%
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
PGR, OMID, ACI, More
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 GAAP EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $304 million versus the consensus estimate of $288.98 million.
Non-GAAP income for the first quarter ended March 31, 2017 was $35 million, compared to non-GAAP loss of $29 million for the quarter ended March 31, 2016.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Boeing delivers 161 commercial jets and 33 defense units in Q3 2026
- Freedom Broker Downgrades Taylor Devices, Inc. (TAYD) to Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
